What did Anthropic acquire Coefficient Bio for?

Anthropic acquired Coefficient Bio in a stock deal reportedly valued at $400 million.

What does Coefficient Bio do?

Coefficient Bio uses artificial intelligence to make drug discovery and other biological research more efficient.

Who founded Coefficient Bio?

Coefficient Bio was founded by Samuel Stanton and Nathan C. Frey, who previously worked in computational drug discovery at Genentech.

Home / Business and Economy / Anthropic Buys AI Drug Discovery Startup

Anthropic Buys AI Drug Discovery Startup

4 Apr

•

Summary

Anthropic acquired Coefficient Bio for $400 million in stock.
Coefficient Bio uses AI to accelerate drug discovery.
The startup's founders previously worked at Genentech.

Anthropic Buys AI Drug Discovery Startup

AI powerhouse Anthropic has finalized the acquisition of Coefficient Bio, a recently launched biotech AI startup, in a significant stock deal reportedly valued at $400 million. This strategic acquisition underscores Anthropic's expanding commitment to the healthcare and life sciences sectors.

Coefficient Bio, founded only eight months prior, was established by Samuel Stanton and Nathan C. Frey. Both founders bring extensive experience in computational drug discovery, having previously contributed to Genentech's Prescient Design team. The startup has been leveraging artificial intelligence to streamline the processes involved in discovering new drugs and advancing biological research.

The integration of Coefficient Bio's team, numbering around 10 individuals, into Anthropic's existing health and life science division is anticipated. This move is expected to fortify Anthropic's efforts in scientific research and discovery within these critical domains.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.